From The Cochrane Library, Issue 3, 2003. Oxford: Update Software Ltd. All rights reserved.

Homocysteine lowering interventions for peripheral arterial disease and bypass grafts (Cochrane Review)

Hansrani M, Stansby G

ABSTRACT

Order full review
View and/or submit comments
What's new in this issue
Search abstracts
Browse alphabetical list of titles
Browse by Review Group

A substantive amendment to this systematic review was last made on 08 March 2002. Cochrane reviews are regularly checked and updated if necessary.

Background: Elevated plasma levels of the amino acid homocysteine (hyperhomocysteinaemia) are associated with hardening or blocking of the arteries (atherosclerosis) In addition, there is a poorer prognosis, both in the progression of the disease and outcome after therapy. Treatment to lower homocysteine levels has been shown to be both effective and cheap in healthy volunteers. However, the impact of reducing homocysteine levels on the progression of atherosclerosis and patency of vessels after treatment for atherosclerosis is still unknown and forms the basis for this review.

Objectives: To assess the effects of plasma homocysteine-lowering therapy on the clinical progression of disease in patients with peripheral arterial disease (PAD) and hyperhomocysteinaemia, including, as a subset, those who have undergone surgical or radiological intervention.

Search strategy: The reviewers (MH,GS) searched the Cochrane Peripheral Vascular Diseases Group trials register, the Cochrane Controlled trials register (2002, Issue1), MEDLINE, EMBASE and reference lists of relevant articles.

Selection criteria: Randomised trials of the treatment of hyperhomocysteinaemia in patients with peripheral arterial disease, before and after surgical or radiological intervention versus no treatment for hyperhomocysteinaemia.

Data collection and analysis: Two reviewers (MH,GS) independently assessed trial quality and extracted data. Information on adverse events was collected from the trials.

Main results: There are currently no randomised trials available for analysis.

Reviewers' conclusions: Well constructed trials assessing the impact of the treatment of hyperhomocysteinaemia in patients with peripheral arterial disease are urgently required.

Citation: Hansrani M, Stansby G. Homocysteine lowering interventions for peripheral arterial disease and bypass grafts (Cochrane Review). In: The Cochrane Library, Issue 3, 2003. Oxford: Update Software.



This is an abstract of a regularly updated, systematic review prepared and maintained by the Cochrane Collaboration. The full text of the review is available in The Cochrane Library (ISSN 1464-780X).

The Cochrane Library is designed and produced by Update Software Ltd.

Update Software Ltd, Summertown Pavilion, Middle Way, Oxford OX2 7LG, UK
(Tel:+44 1865 513902; Fax:+44 1865 516918)

File Reference: AB003285.htm